💰 Financial Performance

Revenue Growth by Segment

For the 9-month fiscal year ended March 31, 2025, the company reported total sales of INR 3,374 Cr, representing a 3% growth compared to the same period last year. In the quarter ended September 30, 2025 (Q2 FY26), sales reached INR 1,150 Cr, a 1% increase YoY. Segment-specific percentage growth for Feminine Care and Health Care was not individually disclosed, though both contributed to the balanced growth.

Geographic Revenue Split

The company does not provide a precise percentage split by region; however, management noted that rural demand is showing a healthy recovery while urban demand remains soft. The company operates primarily in the Indian market with foreign exchange earnings of INR 126.58 Cr for the fiscal year ended March 31, 2025.

Profitability Margins

Operating profit margin improved to 26% in FY 2024-25 from 23% in the previous year, a 13% increase. Net profit margin rose to 19% from 16% in the same period, an 18% improvement. Structural margins have improved by approximately 250 bps over a 5-year basis, and net margins improved by ~60 bps in the most recent period despite cost inflation.

EBITDA Margin

While EBITDA is not explicitly named, the Operating Profit Margin stands at 26% for FY 2024-25. Profit After Tax (PAT) for the 9-month period ended March 31, 2025, was INR 636 Cr, up 7% YoY. For Q2 FY26, PAT was INR 210 Cr.

Capital Expenditure

Historical capital expenditure is not disclosed as a specific INR figure, but the company emphasizes an asset-efficient model, noting that Return on Equity (ROE) has tripled over the last 10 years. Return on Networth was reported at 84% for FY 2024-25.

Credit Rating & Borrowing

The company reported finance costs of INR 3.67 Cr for the 9-month period ended March 31, 2025. Specific credit ratings and interest rate percentages were not disclosed in the provided documents.

⚙️ Operational Drivers

Raw Materials

The company identified 'materials and manpower' as primary cost drivers, which experienced mid-single digit cost inflation (approx. 4-6%). Specific chemical or substrate names were not disclosed, but these materials are essential for the production of Whisper sanitary pads and Vicks healthcare products.

Import Sources

Not specifically disclosed, though the company reported a significant foreign exchange outgo of INR 482.22 Cr for FY 2024-25, suggesting substantial international sourcing of raw materials or finished goods.

Capacity Expansion

Current installed capacity figures were not disclosed. The company focuses on 'Supply 3.0' and 'Advance Ordering' to optimize the existing supply chain rather than detailing specific MTPA expansions.

Raw Material Costs

Cost of raw and packing materials consumed was INR 361.89 Cr for the 9-month period ended March 31, 2025. The company manages these costs through a 'productivity muscle' which delivered INR 93 Cr in savings during FY 2024-25 to offset mid-single digit inflation.

Manufacturing Efficiency

Efficiency is driven by 'Productivity' interventions which saved INR 93 Cr. The company aims for 'Supply 3.0' to make advance ordering a reality, reducing waste and improving response times.

Logistics & Distribution

Not disclosed as a specific percentage of revenue, but identified as a component of the 'Productivity' strategy to fuel reinvestment into brand superiority.

📈 Strategic Growth

Expected Growth Rate

6-8%

Growth Strategy

Growth is driven by an 'Integrated Growth Strategy' focusing on five vectors: a superior product portfolio, superiority in packaging and communication, productivity to fuel investment, constructive disruption (AI/ML in retail), and an agile organization. A key pillar is doubling the e-commerce business and collaborating with creators to drive demand.

Products & Services

Feminine hygiene products (sanitary pads and pants) and healthcare products (cough drops, vaporubs, and inhalants).

Brand Portfolio

Whisper (including Whisper Ultra XL and Whisper Period Pants) and Vicks (including Vicks Double Power Cough Drops).

New Products/Services

Recent launches include Whisper Ultra XL, Vicks Double Power Cough Drops, and Whisper Period Pants. These innovations are intended to grow the category and delight consumers, though specific revenue contribution percentages for each were not disclosed.

Market Expansion

The company is focusing on e-commerce and quick-commerce (Q-comm) platforms to ensure 'personalized availability.' It is also targeting rural recovery to offset soft urban demand.

Market Share & Ranking

Not disclosed in the documents.

Strategic Alliances

The company collaborates with quick-commerce partners to co-create superior consumer experiences and uses AI/ML models for retail execution.

🌍 External Factors

Industry Trends

The industry is seeing a shift toward e-commerce and quick-commerce, with PGHH doubling its e-commerce business. There is a trend toward 'premiumization' in feminine care (e.g., period pants) and a recovery in rural consumption patterns.

Competitive Landscape

The company competes in the feminine hygiene and healthcare sectors. It focuses on 'constructive disruption' and 'superiority' to maintain brand choice against competitors.

Competitive Moat

The moat is built on brand equity (Whisper, Vicks) and 'Superiority' across product performance and retail execution. This is sustained by a 10-year track record of 6% sales CAGR and 8% PAT CAGR, and a tripling of ROE.

Macro Economic Sensitivity

The company is sensitive to macroeconomic environments, particularly urban demand softness and material cost inflation. A mid-single digit increase in costs is currently being managed through productivity savings.

Consumer Behavior

Consumers are increasingly using digital platforms and seeking superior product performance. The company is responding by using creators for demand generation and focusing on 'daily use' categories.

Geopolitical Risks

Not explicitly detailed, but the company follows P&G's global standards and monitors regulatory changes to mitigate international trade risks.

⚖️ Regulatory & Governance

Industry Regulations

Operations are governed by the Companies Act, 2013 and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company also complies with global anti-corruption and data privacy standards.

Environmental Compliance

The company has adopted P&G’s global standards and Worldwide Business Conduct Manual as its business responsibility policy. Specific ESG cost figures in INR were not disclosed.

Taxation Policy Impact

The company follows Indian accounting standards (Ind AS). While the specific tax rate was not listed, the company reported a dividend of INR 175 per equity share, reflecting strong post-tax cash flows.

Legal Contingencies

The company maintains adequate internal financial controls and systems to ensure compliance with all applicable laws. Specific pending court case values in INR were not disclosed.

⚠️ Risk Analysis

Key Uncertainties

Key risks include sustained cost inflation in raw materials (mid-single digit impact) and the continued softness of urban demand which could impact top-line growth targets.

Geographic Concentration Risk

The company is heavily concentrated in the Indian market, though it benefits from the global expertise of its parent, P&G USA (70.64% holding).

Third Party Dependencies

The company relies on a network of distributors and vendors who are subjected to 'stringent and responsive' assessment systems to mitigate dependency risks.

Technology Obsolescence Risk

The company mitigates technology risks by investing in AI/ML for retail assortment and 'Supply 3.0' for supply chain optimization.

Credit & Counterparty Risk

Debtors turnover ratio decreased to 12.38 from 18.40, indicating a potential increase in credit period or collection time, which requires monitoring of receivable quality.